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Association of adult
mastocytosis with M541L in the
transmembrane domain of KIT
Editor
Mastocytosis is a disorder characterized by mast cell (MC) prolif-
eration and accumulation within various organs, most commonly
the skin. Multiple KIT mutations have been reported in patients
with adult mastocytosis, but the potential association of specific
KIT mutations with specific subtypes of mastocytosis remains to
be clarified.
We present the case of a 32-year-old caucasian woman who
came to the Dermatology Department complaining of a 12-year
history of multiple, generalized and reddish-brown macules and
papules with positive Darier’s sign. These lesions were more
numerous in the trunk and limbs, and absent from face, palms
and soles.
She had no systemic symptoms and physical examination was
unremarkable.
Skin biopsy showed MC infiltrates in the dermis (Fig. 1), con-
firming the diagnosis of cutaneous mastocytosis.
Full blood count, white blood cell differential and routine
serum biochemistry tests were within normal range. Serum tryp-
tase level was 17.9 ng ⁄ mL (normal: 0.1–11.4 ng ⁄ mL).
The patient had a 46,XX karyotype.
Abdominal ultrasound, PET scan and bone densitometry were
all normal.
Complete bone marrow study showed normal percentage of
bone marrow MCs (BMMCs) (0.04%) which showed aberrant
coexpression of CD25+, CD2+ and also CD33+, CD35+, CD45+,
CD63+, CD69+ and CD59+. Analysis of coding exons 8, 9, 10, 11
and 17 of the KIT gene revealed the presence of a heterozygous
substitution in exon 10, resulting in the substitution of leucine for
methionine at codon 541 (M541L) (Fig. 2). The sequencing of
KIT exon 10, using DNA extracted from oral mucosa cells, con-
firmed that this was a germline mutation.
Human KIT is a protooncogene located at chromosome 4q12
that contains 21 exons, which encode a transmembrane receptor
(kit) with tyrosine kinase (TK) activity. Binding of kit ligand -
stem cell factor (SCF) - to kit receptor is known to activate kit TK,
which results in different biological effects depending on the acti-
vated cell. In MCs, these effects include, among others, cell prolif-
eration and suppression of apoptosis.1
Mutations of KIT are considered to play a key role in the patho-
genesis of mastocytosis. Most frequently, KIT mutations occur at
exon 11 and 17, resulting in aminoacid changes at the juxtamem-
brane and TK domain of kit respectively.2 Furitsu et al. showed
that point mutations in KIT (Asp816Val and Val560Asp) are capa-
ble of inducing constitutive activation of kit.3 Multiple other acti-
vating KIT mutations have been reported in patients with adult
mastocytosis, but few are described in the transmembrane domain
of KIT,1 encoded by exon 10. In our patient, we detected a hetero-
zygous substitution (germline mutation) in exon 10, resulting in
the substitution of leucine for methionine at codon 541 (M541L).
This mutation was described in general population,4 in a family
with piebaldism5 and in two unrelated pairs of apparently identical
twin children with mastocytosis.6 To the best of our knowledge,
however, this is the first time it is reported in an adult patient with
mastocytosis. According to Foster et al., cells expressing M541L
displayed a significantly heightened response to low levels of
SCF,6 suggesting that these cells may have a proliferative and ⁄ or
survival advantage.
Although our patient had elevated serum tryptase levels,
coexpression of both CD2 and CD25 by BMMCs and a KIT
Figure 2 Analysis of coding exons 8, 9, 10, 11 and 17 of the
KIT gene revealed the presence of a heterozygous substitution
in exon 10, resulting in the substitution of leucine for methionine
at codon 541 (M541L).
Figure 1 Mast cell infiltrates in the dermis; toluidine blue stain,
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mutation, she did not meet the World Health Organization
criteria for systemic mastocytosis.7 However, it is important to
underline the presence of the aberrant CD25 and CD2 immuno-
phenotype, as this is present in virtually all patients with systemic
mastocytosis.2 Additionally, CD25 seems to be a marker for
neoplastic MCs and its expression indicates histologically occult
bone marrow infiltration,8 which could be an indication for
additional investigation.9
In conclusion, we would like to emphasize that this is the first
time that M541L KIT mutation is reported in an adult patient
with mastocytosis. Although the role of this mutant form of KIT
in the pathogenesis of the disease is still unclear, in our patient,
it is associated with aberrant MC immunophenotype. From our
point of view, although without systemic mastocytosis criteria,
these patients should maintain regular clinical evaluation. Further
studies will be required as all these are important prognosis factors
determining these patients’ follow-up.
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Achilles’ heel in dermatology
Editor
We read with interest the case report of intertriginous drug erup-
tion (baboon syndrome) induced by loflazepate ethyl, described
by Watanabe et al.1 In particular, we appreciated how the authors
solved the diagnostic doubt between friction dermatitis and drug
eruption with the comprehensive diagnosis of drug eruption
restrictedly localized on the frictional sites.
Dermatological literature is replete with similar cases where one
or more cutaneous districts, for different reasons, become prone
to harbouring heterogeneous skin disorders. For example, in 2002,
Carrasco et al. published a case of drug eruption secondary to acy-
clovir with recall phenomenon in a dermatome previously affected
by herpes zoster.2 The eruption, consisting of small erythematous
macules and papules, was widespread, but the most striking fea-
ture was represented by the confluence of the lesions along the
dermatome previously involved by herpes zoster. The authors con-
sidered it as an example of recall dermatitis (or recall phenome-
non) since the generalized rash due to acyclovir was more intense
in the dermatome previously compromised by the herpetic infec-
tion. Recall phenomenon, however, refers to drug-induced (often
chemotherapy-induced) reactivation of an antecedent tissue dam-
age caused by radiotherapy, sunburn, mechanical injury or aller-
gen injections. In the case reported by Carrasco et al., no
irradiation, no trauma, no immunization had previously ‘marked’
the cutaneous region that became the site of the lesional conflu-
ence. The only damage suffered by this region had been the her-
petic infection, which itself could have compromised the local
immune balance thus favouring a particular concentration of the
acyclovir-induced rash. In this light, the above case report could
be viewed as an example of Wolf’s isotopic response, which refers
to the occurrence of a new skin disorder (in this case a drug-reac-
tion) at the site of a previous, unrelated and healed cutaneous dis-
ease, in most cases as a herpes zoster infection.3,4 The question
was already raised by Mizukawa and Shiohara, who also took into
consideration the possibility of a fixed drug eruption appearing in
a striking linear pattern as a consequence of the previous zoster
episode.5
We think that this question and similar ones are merely seman-
tic questions. In fact, recall dermatitis, Wolf ’s isotopic response
and fixed-drug eruption can all be considered as different aspects
of a novel, unifying concept, named the immunocompromised
district,6 which somehow evokes the ancient, mythological notion
of Achilles’ heel. The concept encompasses heterogeneous clinical
events, such as herpetic infections, radiation dermatitis, sunburns,
mechanical (including frictional) traumas, vaccinations and
chronic lymph stasis, which can selectively damage and immuno-
logically mark the cutaneous region they act upon. After the caus-
ing event has disappeared, the affected region may show clinically
normal, but its immune behaviour often remains compromised
forever. The immunocompromised district becomes a weak,
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